- Home
- PLSE vs CVAC Comparison
PLSE vs CVAC Comparison
Compare PLSE & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLSE
- CVAC
- Stock Information
- Founded
- PLSE 2014
- CVAC 2000
- Country
- PLSE United States
- CVAC Germany
- Employees
- PLSE N/A
- CVAC N/A
- Industry
- PLSE Medical/Dental Instruments
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- PLSE Health Care
- CVAC Health Care
- Exchange
- PLSE Nasdaq
- CVAC Nasdaq
- Market Cap
- PLSE 1.2B
- CVAC 924.3M
- IPO Year
- PLSE 2016
- CVAC 2020
- Fundamental
- Price
- PLSE $19.74
- CVAC $3.87
- Analyst Decision
- PLSE
- CVAC Hold
- Analyst Count
- PLSE 0
- CVAC 3
- Target Price
- PLSE N/A
- CVAC $10.00
- AVG Volume (30 Days)
- PLSE 133.6K
- CVAC 1.2M
- Earning Date
- PLSE 10-30-2024
- CVAC 11-12-2024
- Dividend Yield
- PLSE N/A
- CVAC N/A
- EPS Growth
- PLSE N/A
- CVAC N/A
- EPS
- PLSE N/A
- CVAC N/A
- Revenue
- PLSE N/A
- CVAC $70,565,734.00
- Revenue This Year
- PLSE N/A
- CVAC $742.57
- Revenue Next Year
- PLSE N/A
- CVAC N/A
- P/E Ratio
- PLSE N/A
- CVAC N/A
- Revenue Growth
- PLSE N/A
- CVAC 75.11
- 52 Week Low
- PLSE $6.60
- CVAC $2.22
- 52 Week High
- PLSE $22.69
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- PLSE 58.11
- CVAC 53.55
- Support Level
- PLSE $17.35
- CVAC $3.70
- Resistance Level
- PLSE $19.90
- CVAC $4.08
- Average True Range (ATR)
- PLSE 1.05
- CVAC 0.28
- MACD
- PLSE 0.15
- CVAC -0.06
- Stochastic Oscillator
- PLSE 80.47
- CVAC 20.71
About PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.